ESMO 2022 | Combining 1L chemo-immunotherapy with oleclumab in patients with advanced TNBC

Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium, discusses the rationale behind the randomized Phase II SYNERGY (NCT03616886) trial investigating first-line durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC). The adenosine pathway is involved in the immunosuppression of the tumor microenvironment, so inhibiting the adenosine pathway may enhance the benefit to immune checkpoint blockades. Additionally, CD73, which is the enzyme responsible for the reduction of adenosine, has been shown to be overexpressed and associated with low immune infiltration and a worse outcome in patients with TNBC. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.